PSYCHEMEDICS CORP
CIK:0000806517|SEC Filings
Consolidated Statements of Operations and Comprehensive Loss - USD ($) shares in Thousands, $ in Thousands |
12 Months Ended | |
|---|---|---|
Dec. 31, 2024 |
Dec. 31, 2023 |
|
| Revenues | $ 19,685 | $ 22,098 |
| Cost of revenues | 12,584 | 13,685 |
| Gross profit | 7,101 | 8,413 |
| Operating Expenses: | ||
| General and administrative | 5,695 | 7,192 |
| Marketing and selling | 2,550 | 2,998 |
| Research and development | 749 | 1,144 |
| Total Operating Expenses | 8,994 | 11,334 |
| Operating Loss | (1,893) | (2,921) |
| Other Expense: | ||
| Settlements | 2 | 507 |
| Other expense | (21) | (10) |
| Total Other Expense | (23) | (517) |
| Net loss before provision for (benefit from) income taxes | (1,916) | (3,438) |
| Provision for (benefit from) income taxes | (55) | 716 |
| Net loss and comprehensive loss | $ (1,861) | $ (4,154) |
| Basic and diluted net loss per share (in dollars per share) | $ (0.32) | $ (0.72) |
| Weighted average common shares outstanding | ||
| Basic (in shares) | 5,867 | 5,740 |
| Diluted (in shares) | 5,867 | 5,740 |